Pharmacology for Nurses · Psychopharmacologic Drugs
Antidepressants
On this page 9 sections
In 30 seconds
Antidepressants are drug classes used primarily to treat major depressive disorder, but their use extends well beyond mood: many are also used for anxiety disorders, chronic pain syndromes, insomnia, and other conditions. The classic explanation of how they work is the Monoamine hypothesis The idea that depression involves reduced signaling by serotonin, norepinephrine, and dopamine Full entry →: depression is associated with reduced signaling by the monoamine neurotransmitters serotonin (5-HT), norepinephrine (NE), and sometimes dopamine (DA) in key brain circuits, and antidepressants increase the availability of these transmitters at the synapse. Modern models are more nuanced — they emphasize adaptive changes in brain circuits and neuroplasticity that develop over weeks — but the monoamine framework still organizes the drug classes well. The major classes are SSRIs, SNRIs, TCAs, MAOIs, and atypical agents such as bupropion, mirtazapine, and trazodone. A defining feature of the group is the Therapeutic lag The weeks-long delay before mood improvement despite immediate receptor effects Full entry →: mood improvement typically takes weeks, even though receptor effects begin immediately. This lag shapes nursing care — adherence teaching, early adverse-effect monitoring, and suicide risk assessment are priorities from day one, not after the drug "kicks in." This topic covers mechanisms, class differences, and the safety concepts (Serotonin syndrome A toxic excess of serotonin: agitation, fever, rigidity, autonomic instability Full entry →, Discontinuation syndrome Withdrawal-like symptoms after abruptly stopping certain antidepressants Full entry →, and overdose toxicity) that matter most in practice.
Why this matters
Depression is among the most common conditions in virtually every healthcare setting, and antidepressants are among the most frequently prescribed drug classes worldwide. Nurses administer these drugs, monitor their effects and adverse effects, and are often the clinician a person talks to about stopping them. Three safety concepts make this class high-stakes: serotonin syndrome, a potentially fatal drug-interaction emergency; discontinuation syndrome, which occurs when certain antidepressants are stopped abruptly; and overdose toxicity, which is especially dangerous with TCAs because of their cardiac effects. Additionally, some antidepressants carry a boxed warning about increased suicidality risk in children, adolescents, and young adults early in treatment — a reason for close monitoring that nurses operationalize. Understanding each class's mechanism lets the nurse anticipate which adverse effects to expect (anticholinergic effects with TCAs, weight and sexual effects with SSRIs, tyramine reactions with MAOIs) and teach people what to expect during the first weeks of therapy.
The college version
Core Concepts
SSRIs: the first-line workhorse
Selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, escitalopram) block the serotonin transporter (SERT) on presynaptic neurons, leaving more serotonin in the synapse. They are called "selective" because their effect on norepinephrine and dopamine reuptake is minimal. SSRIs are generally first-line because they are effective across many conditions and are relatively forgiving in overdose compared with older classes. Common adverse effects follow from increased serotonin everywhere, not just in mood circuits: gastrointestinal upset early in treatment, insomnia or sedation, sexual dysfunction, and weight changes. Serotonin syndrome risk rises when an SSRI A drug that selectively blocks serotonin reuptake (e.g., sertraline) Full entry → is combined with other serotonergic drugs (e.g., triptans, some opioids, MAOIs, or other antidepressants) — a key teaching and reconciliation point.
SNRIs: adding norepinephrine
Serotonin–norepinephrine reuptake inhibitors (e.g., venlafaxine, duloxetine) block both SERT and the norepinephrine transporter (NET). The added noradrenergic effect can help with energy, concentration, and pain modulation — duloxetine in particular is used for chronic pain conditions. The flip side is more noradrenergic adverse effects: increased blood pressure and heart rate, sweating, and insomnia. Because of the blood-pressure effect, monitoring of vital signs is part of routine care with these agents.
TCAs: effective but dangerous in overdose
Tricyclic antidepressants (e.g., amitriptyline, nortriptyline, imipramine) block reuptake of both serotonin and norepinephrine, but they also block histamine (H1), muscarinic acetylcholine, and alpha-1 adrenergic receptors — producing sedation, anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision, confusion), and orthostatic hypotension. They remain useful for depression, neuropathic pain, and migraine prevention, but their cardiotoxicity in overdose (arrhythmias, conduction block) makes them a leading cause of fatal drug overdose among antidepressant classes. This is why TCAs are prescribed cautiously, dispensed in limited quantities where indicated, and kept away from anyone at risk of self-harm — verify all such decisions against the current reference and prescriber plan.
MAOIs: powerful, interaction-heavy
Monoamine oxidase inhibitors (e.g., phenelzine, tranylcypromine) block the enzyme that breaks down monoamines, raising serotonin, norepinephrine, and dopamine levels. They are effective but reserved for depression that has not responded to other treatments because of two dangerous interactions: serotonin syndrome if combined with other serotonergic drugs (including SSRIs — never combined), and hypertensive crisis if the person eats foods rich in tyramine (aged cheeses, cured meats, some fermented foods) or takes certain sympathomimetic drugs, because tyramine is normally degraded by MAO in the gut. People taking MAOIs need dietary teaching and must carry this information; a washout period is required when switching to or from other antidepressants. Institutional and pharmacy policies govern how these drugs are managed — verify against current references.
Atypical antidepressants: different levers
The "atypical" agents do not fit the reuptake-inhibitor mold. Bupropion inhibits reuptake of norepinephrine and dopamine (no direct serotonin effect), which makes it useful when serotonin-related adverse effects like sexual dysfunction or sedation are a problem — but it lowers the seizure threshold, so it is avoided in people with seizure disorders or eating disorders. Mirtazapine blocks presynaptic alpha-2 receptors (increasing both serotonin and norepinephrine release) and also blocks 5-HT2, 5-HT3, and H1 receptors; the H1 blockade causes sedation and appetite stimulation, which can be helpful in depression with insomnia and poor appetite. Trazodone blocks 5-HT2 receptors and inhibits serotonin reuptake; at the low doses often used for sleep it is mainly sedating (H1/5-HT2 effects), while at antidepressant doses it is serotonergic.
The therapeutic lag and the first weeks
Every class shares a clinical paradox: receptor effects are immediate, but mood improvement takes weeks. The first weeks are therefore the highest-risk period for dropout (the person "feels no better, only side effects") and, for younger people, for the boxed-warning increase in suicidal thinking. Nursing care in this window includes explicit teaching about the expected timeline, early adverse-effect management, adherence support, and scheduled follow-up. All prescribing decisions, monitoring schedules, and suicide-risk protocols follow current guidelines and institutional policy — verify against current references.
Common Confusions
| Do Not Confuse | With | Difference |
|---|---|---|
| SSRIs and SNRIs | TCAs | SSRIs/SNRIs selectively block monoamine transporters; TCAs also block H1, muscarinic, and alpha-1 receptors, causing sedation, anticholinergic effects, and overdose cardiotoxicity |
| Serotonin syndrome | Discontinuation syndrome | Serotonin syndrome is a toxic excess of serotonin (fever, rigidity, autonomic instability) — an emergency; discontinuation syndrome is withdrawal from stopping a drug abruptly — unpleasant, not usually life-threatening |
| Feeling worse in week 1 | Drug failure | Early adverse effects with no mood benefit yet are expected (therapeutic lag); drug failure is judged after weeks of adequate therapy |
| Depression | Sadness | Depression is a persistent syndrome affecting mood, sleep, appetite, energy, and function; sadness is a normal emotion. Medication is one part of a treatment plan, not a "happiness pill" |
| Bupropion (NE/DA) | SSRI (5-HT) | Different mechanisms and different adverse profiles; bupropion lowers the seizure threshold and is avoided in seizure disorders |
| Tapering after stopping | Abrupt discontinuation | Gradual tapering under prescriber guidance prevents discontinuation syndrome; abrupt stopping invites it |
Eli explains
The same idea, in plain words
Explain it like I’m 10
Think of the brain's mood messages as letters carried between nerve cells. Depression can happen when there are too few letters getting through. Antidepressants are like helpers that make more letters available — some make the mailbox stay open longer, some add a second mail carrier, and a few slow down the letter-destroying machine. The helpers take a few weeks to reorganize the mailroom, which is why the medicine doesn't feel like it's working right away, and some helpers can cause trouble if they are mixed with the wrong food or medicine.
Worked example
Teaching through the therapeutic lag. A person starting an SSRI for depression tells the nurse on day 5, "This medicine is making me nauseous and I don't feel any better — I'm going to stop it." The nurse validates the frustration, then teaches: the receptors are affected immediately, but the brain's circuits take weeks to adapt, so feeling worse before feeling better is expected; the nausea usually settles, and stopping abruptly could bring withdrawal-like symptoms. The nurse schedules close follow-up, asks directly about any new thoughts of self-harm (per the suicidality monitoring plan), and documents the teaching. Before discharge, the nurse reviews the medication list and flags that the person also uses a triptan for migraines — a combination that raises serotonin syndrome risk — and the provider adjusts the plan accordingly. The scenario shows the nurse's real job with this class: not just giving the drug, but managing the first weeks, the interactions, and the person's experience of the medicine.
Key takeaways
- Monoamine hypothesis: depression is linked to reduced 5-HT/NE/DA signaling; antidepressants raise monoamine availability at the synapse.
- SSRIs block serotonin reuptake (first-line); SNRIs block serotonin + norepinephrine reuptake (watch blood pressure); TCAs add anticholinergic, antihistaminic, and alpha-1 blocking effects (cardiotoxic in overdose); MAOIs block monoamine breakdown (tyramine + serotonin syndrome hazards).
- Therapeutic lag: improvement takes weeks — adverse effects appear first; adherence teaching and suicide-risk monitoring start on day one.
- Serotonin syndrome: fever, agitation, muscle rigidity, autonomic instability — an emergency when serotonergic drugs are combined; know the interaction pairs (SSRI/SNRI + MAOI, triptan, certain opioids).
- Discontinuation syndrome: abrupt stopping of SSRIs/SNRIs/TCAs can cause flu-like symptoms, dizziness, and mood swings — taper under prescriber guidance.
- MAOI + tyramine foods can cause hypertensive crisis; MAOIs require dietary teaching and washout periods.
- Some antidepressants carry a boxed warning on suicidality in children, adolescents, and young adults early in treatment — close monitoring is the nursing response.
- Person-first language: a person receiving treatment for depression, not a "depressed patient."
Check yourself
5 review questions from the chapter. Try each one, then open the answer.
Why do antidepressants take weeks to improve mood even though their receptor effects are immediate?
Show answer
Receptor effects (e.g., reuptake blockade) are immediate, but the therapeutic benefit depends on slower adaptive changes in brain circuits and neuroplasticity that develop over weeks — the therapeutic lag.
What makes TCAs more dangerous in overdose than SSRIs?
Show answer
TCAs block cardiac sodium channels and can cause arrhythmias and conduction block in overdose, making them a leading cause of fatal antidepressant overdose; SSRIs are far less cardiotoxic in overdose.
What are the two major interaction hazards of MAOIs, and what teaching follows from each?
Show answer
Hypertensive crisis from tyramine-containing foods or sympathomimetic drugs (requiring dietary teaching), and serotonin syndrome from combining with other serotonergic drugs (requiring interaction checks and washout periods when switching).
A person on an SSRI adds a triptan for migraine. What syndrome should the nurse watch for, and what are its key signs?
Show answer
Serotonin syndrome — watch for a triad of mental status changes (agitation, confusion), autonomic instability (fever, sweating, tachycardia, blood pressure changes), and neuromuscular findings (tremor, rigidity, hyperreflexia). It is a medical emergency.
What is the difference between serotonin syndrome and discontinuation syndrome?
Show answer
Serotonin syndrome is caused by an excess of serotonin (usually from combining serotonergic drugs) and is life-threatening; discontinuation syndrome is caused by abruptly stopping an antidepressant and produces flu-like, dizziness, and mood symptoms that resolve with a gradual taper.
Study tools & related lessonsKey vocabulary · Related
Key vocabulary
- Monoamine hypothesis
- The idea that depression involves reduced signaling by serotonin, norepinephrine, and dopamine
- SSRI
- A drug that selectively blocks serotonin reuptake (e.g., sertraline)
- SNRI
- A drug that blocks both serotonin and norepinephrine reuptake (e.g., duloxetine)
- TCA
- An older antidepressant that also blocks histamine, muscarinic, and alpha-1 receptors (e.g., amitriptyline)
- MAOI
- A drug that inhibits monoamine oxidase, raising monoamine levels (e.g., phenelzine)
- Serotonin syndrome
- A toxic excess of serotonin: agitation, fever, rigidity, autonomic instability
- Discontinuation syndrome
- Withdrawal-like symptoms after abruptly stopping certain antidepressants
- Therapeutic lag
- The weeks-long delay before mood improvement despite immediate receptor effects
Sources & references
This lesson was adapted from the open educational references above; their licenses and attributions are preserved. See Copyright & Licensing.
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.